Hosted by Matt Aldrich & Dana Prescott
Downloads
More from: Biologic Wars: Rheumatology Debate Series
The ORAL Surveillance JAK Inhibitor Controversy
ORAL Surveillance showed tofacitinib carried higher cardiovascular and malignancy risk than anti-TNF in high-risk RA patients - triggering a class-wide boxed warning. But was the signal overgeneralised? Sarah Mitchell and James Carter unpack the data, the controversy, and how to make the JAKi-vs-biologic decision in 2026.
Chasing Absolute Zero In Rheumatoid Arthritis
Treat-to-target transformed RA outcomes - not through new drugs but through rigorous measurement and escalation discipline. Sarah Mitchell and James Carter cover the evidence base, the disease activity tools, the window of opportunity in early RA, and when tapering biologics in sustained remission is safe.
Stopping Spinal Fusion Or Protecting The Gut?
PsA is not RA with skin, and axSpA is not RA in the spine. The biologic hierarchy shifts significantly across the spondyloarthropathy spectrum - IL-17 and IL-23 inhibitors dominate, anti-TNF has uveitis caveats, and IBD comorbidity changes everything. Sarah Mitchell and James Carter explain how EULAR 2026 data shapes the choices.
- Biosimilars are approved to stringent regulatory standards - approved biosimilars are not inferior products
- NOR-SWITCH and multiple subsequent studies consistently show switching from reference biologic to biosimilar is safe and maintains remission
- The nocebo effect is real - patient counselling about biosimilar equivalence is a clinical responsibility that directly affects discontinuation rates
- NHS England biosimilar adoption reduced adalimumab spend by more than 50% while treating more patients; this dividend funded access to newer on-patent biologics
POD-2026-020 - 06/26
Matt Aldrich is a medical science communicator based in Boston. With a background in biomedical research and health journalism, he specialises in translating complex clinical trial data into accessible conversations for healthcare professionals.
Cite This Article
Team TLSFE. Why cheaper humira alternatives face resistance. The Life Science Feed. Published June 1, 2026. Updated June 1, 2026. Accessed June 1, 2026. https://thelifesciencefeed.com/rheumatology/arthritis-rheumatoid/insights/why-cheaper-humira-alternatives-face-resistance.
Licence & Rights
© 2026 The Life Science Feed. All rights reserved. Unless otherwise indicated, all content is the property of The Life Science Feed and may not be reproduced, distributed, or transmitted in any form or by any means without prior written permission.
Podcast Disclaimer
Editorial & AI Standards
All content is researched from peer-reviewed, open-access sources — published trial data, clinical guidelines, and regulatory filings. AI tools are used solely to structure and summarise that evidence; no AI-generated conclusions appear without editor verification against the primary source.
Every article is reviewed by a named editor before publication. Source citations are listed in the References section. This content does not represent the views of any pharmaceutical company, medical device manufacturer, or healthcare provider.
References
[1] Jorgensen KK et al. NOR-SWITCH. Lancet. 2017;389:2304-2316
[2] NHS England. Biosimilar medicines: a guide for primary care. 2022
[3] Kay J et al. Ann Rheum Dis. 2018;77:1658-1665
[4] Smolen JS et al. EULAR RA Recommendations 2023. Ann Rheum Dis. 2023
